imatinib mesylate has been researched along with Anaplastic Ependymoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dieckmann, K; Fakhrai, N; Hainfellner, J; Marosi, C; Nemeth, A; Neophytou, P; Prayer, D | 1 |
1 other study(ies) available for imatinib mesylate and Anaplastic Ependymoma
| Article | Year |
|---|---|
Recurrent spinal ependymoma showing partial remission under Imatimib.
Topics: Adult; Antineoplastic Agents; Benzamides; Ependymoma; Female; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Spinal Cord Neoplasms | 2004 |